CBN for Sleep: What the Research Actually Shows

CBN is widely sold as a cannabinoid for sleep, but the marketing is ahead of the evidence. Human trials have found possible benefits for selected sleep measures, including nighttime awakenings, sleep onset, and self-rated sleep disturbance. They have not consistently met their primary endpoints, and they do not establish that a retail CBN product treats insomnia.

The most useful way to read this research is outcome by outcome. A change in one secondary measure does not mean CBN improved sleep as a whole. A result from a product containing THC, CBD, melatonin, or botanicals also cannot show what CBN does by itself.

What is CBN?

Cannabinol, usually shortened to CBN, is a minor cannabinoid. It forms as delta-9-tetrahydrocannabinol (THC) undergoes oxidative degradation, a process accelerated by exposure to oxygen, light, and heat. CBN has lower affinity for the cannabinoid 1 receptor than THC, but that does not make it an inactive ingredient ¹.

CBN is not:

• The same compound as CBD
• THC-free by definition
• Melatonin
• A proven natural sedative
• An FDA-approved treatment for insomnia

CBN is sometimes described as nonintoxicating. That description is too certain. In a recent CBN-only trial, a high study amount produced modest subjective drug effects and subtle changes on some next-day performance measures. It did not produce the same profile as THC, but the study does not justify promising that CBN can never make someone feel altered or impaired ¹.

Does CBN help you sleep?

The best answer is that CBN has early human evidence, but its benefit remains uncertain. Three randomized trials of CBN without THC give the clearest picture.

A single-night trial in adults with insomnia

A 2026 randomized crossover trial enrolled 20 adults with physician-diagnosed insomnia disorder. Each participant spent one study night after 30 mg CBN, one after 300 mg CBN, and one after placebo, with at least two weeks between treatments. The amounts describe the experiment and are not consumer dose recommendations ¹.

The primary outcome was wake after sleep onset, measured with overnight polysomnography. Neither CBN amount produced a statistically significant improvement. The estimated differences from placebo were about four fewer minutes with 30 mg and six fewer minutes with 300 mg, and the confidence intervals included no benefit ¹.

Some secondary outcomes moved in a favorable direction with 300 mg:

• Sleep onset latency was about seven minutes shorter.
• The proportion of stage N2 sleep was about 3.8 percentage points higher.
• Participants rated their sleep quality more favorably.
• The electroencephalographic arousal index was lower.

Neither amount changed the proportion of deep N3 sleep or REM sleep. The trial therefore does not support claims that CBN increases deep sleep or REM sleep. It also cannot establish sustained benefit because each treatment was tested for one night ¹.

This was a carefully controlled study with objective sleep measurement, but it was a small proof-of-concept trial with no formal power calculation and many secondary, tertiary, and safety outcomes. The secondary findings are useful signals for larger trials, not proof that 300 mg is an effective insomnia dose ¹.

Seven nights in adults who reported poor sleep

An earlier industry-funded randomized trial studied 293 adults aged 18 to 55 who rated their sleep as poor or very poor. Participants received placebo, 20 mg CBN, or 20 mg CBN combined with one of three CBD amounts for seven nights ².

CBN alone did not significantly improve the primary outcome, self-rated sleep quality, compared with placebo. It did reduce the reported number of awakenings and improve a broader self-reported sleep-disturbance score. It did not change reported sleep onset latency, wake after sleep onset, or daytime fatigue. Adding CBD did not improve the CBN results ².

These results point to a possible sleep-maintenance signal, but they rely on self-report and a short treatment period. The participants had poor sleep rather than a confirmed insomnia diagnosis. The study was funded by Canopy Growth, and the listed authors were affiliated with Canopy Growth or Wana Brands ².

Four weeks of a proprietary CBN softgel

A 2024 decentralized trial randomized 1,020 adults reporting sleep disturbance to placebo, 4 mg melatonin, or a proprietary softgel containing 25, 50, or 100 mg CBN. Over four weeks, self-reported sleep-disturbance scores improved at a faster rate in each CBN group than in the placebo group ³.

An important qualification was easy to miss: none of the CBN groups was more likely than placebo to reach the study's predefined minimum clinically important improvement. The trial did not use polysomnography or actigraphy, and it did not establish that participants had insomnia disorder. The product manufacturer funded the data collection under contract, and several authors worked for the company that conducted the study ³.

The trial supports further study of repeated CBN use. It does not identify a best amount, prove equivalence to melatonin, or establish objective improvement in sleep ³.

Why CBN blends answer a different question

A product labeled "CBN sleep" may also contain THC, CBD, melatonin, or several botanical ingredients. Any benefit or side effect could come from one ingredient, an interaction between ingredients, or the complete formulation.

For example, a small two-week crossover trial found improved insomnia symptoms with a sublingual cannabis extract. The extract contained THC, CBN, CBD, and terpenes, with 20 mg THC, 2 mg CBN, and 1 mg CBD per milliliter. Participants could use either 0.5 or 1 milliliter. Because THC was the dominant cannabinoid and the formulation contained several active constituents, the result cannot be credited to CBN ⁴.

The same rule applies to retail gummies. A testimonial or trial involving a THC-CBN gummy does not establish that a CBN isolate works. A melatonin-CBN product does not answer whether CBN added anything.

What the research does and does not support

Current human evidence supports a cautious interpretation:

• Possible benefit: Some trials found fewer reported awakenings, lower self-reported sleep disturbance, shorter objective sleep onset, or better subjective sleep quality.
• Inconsistent primary results: The seven-night trial did not meet its primary sleep-quality endpoint, and the single-night insomnia trial did not improve its primary objective endpoint of wake after sleep onset.
• No established sleep-stage benefit: The insomnia trial found more N2 sleep with 300 mg, but no increase in N3 or REM sleep. N2 is not the same as deep sleep.
• No established effect on anxiety or pain: The four-week trial found no difference from placebo for anxiety or pain. CBN should not be presented as treating those problems on this evidence ³.
• No long-term answer: The controlled sleep trials lasted one night, seven nights, or four weeks. They do not establish sustained benefit, tolerance, withdrawal risk, dependence risk, or long-term organ safety.

CBN may eventually prove useful for a specific sleep problem or population. The available trials do not yet show who is most likely to benefit.

Is there a recommended CBN dose for sleep?

No evidence-based CBN dose for sleep has been established.

Published trials have tested amounts from 20 mg to 300 mg, but that is not a recommended range. The studies used different formulations, populations, outcomes, and treatment periods. The highest amount produced some positive secondary results in a single-night trial, while the primary outcome remained negative. The four-week trial did not show that a higher amount worked better than a lower one ^{1 3}.

Research timing is not a dosing instruction either. For example, the single-night trial administered CBN two hours before the participant's usual lights-out time under observation and with standardized meals. A retail oil or gummy may have different ingredients and absorption. Human research has not established one onset time, duration, or ideal bedtime schedule that applies across CBN products ¹.

If you are considering CBN, ask a pharmacist or clinician to review the exact product and your medications. Do not use a research amount as a self-treatment target.

Side effects and next-day impairment

Short studies cannot define the full safety profile.

In the single-night insomnia trial, all 20 participants reported at least one adverse event across the three treatment arms. Researchers recorded 91 mild events after 300 mg CBN, 73 after 30 mg, and 82 after placebo, plus one moderate event after placebo. Common questionnaire responses included fatigue, drowsiness, lethargy, dry mouth, dizziness, nausea or vomiting, and feeling drunk or intoxicated. There were no serious events or withdrawals, but the similar event count with placebo and the small sample make it difficult to estimate CBN-specific rates ¹.

That trial did not find worse lane weaving on a driving simulator. However, 300 mg increased speed variability during a divided-attention task, changed some other driving measures, and produced mild subjective drug effects. This is not proof of safe driving after CBN, especially after repeated use or when a retail product contains THC, CBD, alcohol, melatonin, or another sedating ingredient ¹.

Avoid driving or safety-critical work if you feel sleepy, slowed, dizzy, or altered. People in transportation, healthcare, public safety, the military, or other tested occupations should check their employer's policy before using any cannabinoid product.

Interactions and higher-risk groups

CBN-specific interaction studies are inadequate. The recent insomnia trial excluded people using central nervous system-active drugs and medications that could alter cannabinoid metabolism. Its safety findings therefore do not answer what happens when CBN is combined with prescription sleep medicines, sedating antihistamines, anxiety medicines, opioids, alcohol, or many other drugs ¹.

Ask a pharmacist or prescribing clinician before combining CBN with medicines or other sleep products. The review should include every active ingredient, not only CBN. CBD, THC, melatonin, and botanical extracts have their own evidence and interaction concerns.

Avoid retail CBN, or discuss it first with an appropriate clinician, in these situations:

• Pregnancy or breastfeeding: CBN has not been shown safe in either group. Public-health guidance recommends avoiding cannabis products during pregnancy and breastfeeding because fetal and infant effects remain uncertain and products may contain THC or other contaminants ^{5 6}.
• Children and teenagers: CBN has not been established as a pediatric sleep treatment. Keep oils, gummies, and other products locked away. The FDA advises medical evaluation after suspected accidental ingestion of a cannabis-containing product, especially when a child acts unusually or feels ill ⁷.
• Adults older than 65: The diagnosed-insomnia trial ended at age 65, and the seven-night trial ended at age 55. Evidence is insufficient for older adults, especially when medication interactions or fall risk are already concerns ^{1 2}.
• People with other sleep disorders or complex medical conditions: The controlled insomnia trial excluded moderate sleep apnea, sleep-related movement disorders, significant cardiovascular abnormalities, and many medication users. Do not assume its findings apply to these groups ¹.

Could CBN cause a positive drug test?

Standard federal workplace testing looks for THC or a THC metabolite, not CBN itself ⁸.

The practical risk is product composition. A CBN product may intentionally include THC, contain an inaccurately labeled amount, or have trace THC. A study of topical hemp-derived CBD products, not CBN sleep products, found THC in 35% of products and detected it in some products labeled THC-free. That study cannot estimate the drug-test risk from an oral CBN product, but it shows why a marketing label alone is not a guarantee ⁹.

If a positive result could affect your job, license, sport, or military status, the lowest-risk choice is not to use an unapproved cannabinoid product. A "THC-free" claim or laboratory report cannot guarantee a negative test.

How to evaluate a retail CBN product

Product checks cannot prove that CBN will work, but they can reveal important differences between what was studied and what is being sold. Retail cannabinoid labels and therapeutic claims do not receive the same premarket review as an approved drug ^{7 9}.

1. Read the amount per serving. A large number on the front may refer to the whole package rather than one gummy, capsule, or measured oil serving.
2. List every active ingredient. Look for delta-9 THC, delta-8 THC, CBD, melatonin, herbs, and added sleep medicines. "Full spectrum," "broad spectrum," and "isolate" are not substitutes for an ingredient list and measured results.
3. Find a batch-specific laboratory report. The lot number should match the package. Check measured CBN, CBD, and THC rather than relying only on a pass or fail badge. When relevant, review testing for residual solvents, pesticides, heavy metals, and microbes.
4. Check who performed the test. A report should identify the laboratory, method, sample date, and result for the actual batch. A generic certificate posted for every lot is less informative.
5. Ignore disease-treatment language. In the United States, no CBN product has been approved by the FDA to treat insomnia. The FDA has approved only a small number of specific prescription cannabis-derived or cannabis-related drugs for other indications ⁷.

A certificate of analysis is not FDA approval, proof of clinical benefit, or a guarantee that every unit in the batch is identical.

Is CBN legal?

CBN laws vary by country, state, product source, manufacturing method, and THC content. Do not assume a product is legal because its label says "hemp-derived."

In the United States, federal hemp law is in transition. Congress enacted a narrower hemp definition in November 2025, with the amendment scheduled to take effect one year later. The change adds total-THC and per-container conditions and excludes some cannabinoids manufactured outside the plant. State controlled-substance and consumer-product rules can still be stricter, and FDA rules are separate from controlled-substance status ¹⁰.

Check the current law for the exact product where you live and anywhere you plan to travel. Do not carry CBN across a state or national border based only on a retailer's legal claim.

When sleep problems need proper care

CBN should not delay evaluation of persistent insomnia or another sleep disorder. Cognitive behavioral therapy for insomnia (CBT-I) is strongly recommended for chronic insomnia in adults. Sleep hygiene by itself is not considered an adequate treatment for chronic insomnia ¹¹.

Arrange a medical or sleep evaluation if:

• Trouble falling or staying asleep occurs at least three nights a week for about three months
• Poor sleep affects mood, concentration, work, school, or driving
• You snore loudly, gasp, stop breathing, or wake with headaches
• An urge to move the legs or repeated limb movements disrupt sleep
• Sleep problems began with a new medicine, substance, mood change, or health condition
• You rely on several products or increasing amounts to sleep

A clinician can look for insomnia, sleep apnea, restless legs syndrome, circadian disruption, medication effects, pain, or another treatable cause.

Bottom line

CBN is a plausible research target, not an established insomnia treatment. CBN-only trials have found some promising secondary outcomes, but they have not produced consistent primary-endpoint success. The best objective trial involved only 20 people and one night of each treatment.

There is no validated consumer dose, no established long-term safety profile, and no basis for promising more deep sleep, more REM sleep, anxiety relief, pain relief, or freedom from next-day impairment. Mixed cannabinoid products answer a different question because THC, CBD, melatonin, and other ingredients can change both benefits and risks.

If you still want to consider CBN, review the exact formulation with a pharmacist or clinician, treat driving and workplace testing as real concerns, and do not let a retail sleep claim replace care for persistent insomnia.